Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Endocarditis After Transcatheter Pulmonary Valve Replacement

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Obesity as a Causal Risk Factor for Aortic Valve Stenosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Coronary CT Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Effects of Interatrial Shunt on Pulmonary Vascular Function in Heart Failure With Preserved Ejection Fraction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Reply: Enterococcus faecalis Infective Endocarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Transcatheter Aortic Valve Replacement: Role of Multimodality Imaging in Common and Complex Clinical Scenarios

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Simplification of Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The role of the Heart Team in the planning of aortic valve replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Will the Evolut Low Risk trial change my practice?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Doff B McElhinney
  • Lars Sondergaard
  • Aimee K Armstrong
  • Lisa Bergersen
  • Robert F Padera
  • David T Balzer
  • Te-Hsin Lung
  • Felix Berger
  • Evan M Zahn
  • Robert G Gray
  • William E Hellenbrand
  • Jacqueline Kreutzer
  • Andreas Eicken
  • Thomas K Jones
  • Peter Ewert
Vis graf over relationer

BACKGROUND: Endocarditis has emerged as one of the most concerning adverse outcomes in patients with congenital anomalies involving the right ventricular outflow tract (RVOT) and prosthetic valves.

OBJECTIVES: The aim of this study was to evaluate rates and potential risk factors for endocarditis after transcatheter pulmonary valve replacement in the prospective Melody valve trials.

METHODS: All patients in whom a transcatheter pulmonary valve (TPV) was implanted in the RVOT as part of 3 prospective multicenter studies comprised the analytic cohort. The diagnosis of endocarditis and involvement of the TPV were determined by the implanting investigator.

RESULTS: A total of 309 patients underwent transcatheter pulmonary valve replacement (TPVR) and were discharged with a valve in place. The median follow-up duration was 5.1 years, and total observation until study exit was 1,660.3 patient-years. Endocarditis was diagnosed in 46 patients (median 3.1 years after TPVR), and a total of 35 patients were reported to have TPV-related endocarditis (34 at the initial diagnosis, 1 with a second episode). The annualized incidence rate of endocarditis was 3.1% per patient-year and of TPV-related endocarditis was 2.4% per patient-year. At 5 years post-TPVR, freedom from a diagnosis of endocarditis was 89% and freedom from TPV-related endocarditis was 92%. By multivariable analysis, age ≤12 years at implant (hazard ratio: 2.3; 95% confidence interval: 1.2 to 4.4; p = 0.011) and immediate post-implant peak gradient ≥15 mm Hg (2.7; 95% confidence interval: 1.4 to 4.9; p = 0.002) were associated with development of endocarditis and with development of TPV-related endocarditis (age ≤12 years: 2.8; 95% confidence interval: 1.3 to 5.7; p = 0.006; gradient ≥15 mm Hg: 2.6; 95% confidence interval: 1.3 to 5.2; p = 0.008).

CONCLUSIONS: Endocarditis is an important adverse outcome following TVPR in children and adults with post-operative congenital heart disease involving the RVOT. Ongoing efforts to understand, prevent, and optimize management of this complication are paramount in making the best use of TPV therapy. (Melody Transcatheter Pulmonary Valve [TPV] Study: Post Approval Study of the Original Investigational Device Exemption [IDE] Cohort; NCT00740870; Melody Transcatheter Pulmonary Valve Post-Approval Study; NCT01186692; and Melody Transcatheter Pulmonary Valve [TPV] Post-Market Surveillance Study; NCT00688571).

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind72
Udgave nummer22
Sider (fra-til)2717-2728
Antal sider12
ISSN0735-1097
DOI
StatusUdgivet - 4 dec. 2018

ID: 56525245